<?xml version="1.0" encoding="UTF-8"?>
<p id="Par22">A novel DC vaccine, DCP-001, was developed that uniquely combines the positive features of allogeneic DC vaccines and multi-antigen-expressing tumor cell vaccines. DCP-001 consists of mature DC generated through differentiation and maturation of the AML cell line DCOne and as such harbors AML-associated antigens.</p>
